CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 142 enrolled
Drug / intervention
FX-322 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05086276
NCT05086276Phase 2Completed
CompareCT.gov

A Phase 2, Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Multicenter Study to Evaluate the Efficacy of FX-322 Administered by Intratympanic Injection in Adults With Acquired Sensorineural Hearing Loss

Frequency Therapeutics·interventional·Posted Oct 20, 2021·Updated Apr 21, 2023

In Brief

A Phase 2 clinical trial evaluating FX-322 and Placebo for Hearing Loss, Sensorineural and 2 related conditions. Completed, enrolled 142 participants across 26 sites.

Detailed Summary

This is a Phase 2, prospective, randomized, double-blind, placebo-controlled, single-dose, multicenter study to evaluate the efficacy of FX-322, administered by intratympanic injection, in adults with acquired sensorineural hearing loss (SNHL).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHearing Loss, Sensorineural, Noise Induced Hearing Loss, Sudden Hearing Loss
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedOct 20, 2021
Enrollment StartOct 12, 2021
Primary CompletionDec 30, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 4.7 years ago

Interventions

FX-322drug

Active Comparator

Placebodrug

Placebo